Longevity Supplement Stack: What the Evidence Actually Supports

NMN supplements are not worth your money in 2026. I say that not to be contrarian but because the evidence hierarchy demands it, and because the gap between what the longevity supplement market claims and what randomized controlled trials in humans actually show is large enough that someone needs to say it plainly.

The longevity supplement market is large, fast-moving, and prone to overclaiming. A molecule that extends the median lifespan of a specific mouse strain by 10 percent becomes, in marketing copy, a product that will "add years to your life." The underlying study often involved doses impractical in humans, tested in genetically homogeneous lab animals far removed from human metabolic complexity, and was never replicated in a clinical trial.

This page applies a consistent evidentiary framework to the most commonly discussed compounds. It separates what is well-supported from what is promising but uncertain, and from what has already failed clinical translation. It also covers prescription-only candidates with an honest assessment of their current evidence base.

---

A Framework for Evaluating Supplement Claims

The hierarchy matters:

1. Randomized controlled trials (RCTs) in humans with relevant outcomes (mortality, disease incidence, functional measures) are the highest standard.
2. Observational studies in humans can identify associations but cannot establish causation, and are subject to healthy user bias: the tendency for people who take supplements to also engage in other health-promoting behaviors.
3. Animal studies demonstrate mechanism and proof of concept. They routinely fail to translate directly to human effect sizes; many mouse studies use doses that scale to hundreds of grams per day in a human adult.
4. Anecdote and mechanistic speculation contribute nothing to establishing whether a compound works safely in humans at practical doses.

When evaluating a supplement claim, the first question is: where does the evidence sit in this hierarchy, and how large and well-conducted are the human studies?

---

The Strongest Evidence Tier

Creatine Monohydrate (5 g/day)

Creatine is the most evidence-supported ergogenic compound for aging muscle. A meta-analysis of human aging studies reviewed by Candow and colleagues, published in the Journal of Clinical Medicine in 2019, found that creatine supplementation during resistance training significantly increased lean tissue mass (approximately 0.94 to 1.37 kg across meta-analyses), upper and lower body strength, and functional performance in adults aged 57 to 70. These are not small effects in the context of sarcopenia prevention.

Creatine works primarily by increasing phosphocreatine availability in muscle, supporting rapid ATP resynthesis during high-intensity effort, and via plausible anti-catabolic and anti-inflammatory secondary pathways. At 5 g per day (the standard maintenance dose), it is safe for most adults with normal kidney function, with well over two decades of safety data in the literature.

The longevity implication is indirect but real: sarcopenia, the age-related loss of muscle mass and strength, is an independent predictor of mortality. Interventions that slow it extend functional independence.

Omega-3 Fatty Acids (EPA and DHA)

A 2021 meta-analysis of 38 randomized controlled trials covering 149,051 participants, led by Brigham and Women's Hospital researchers and published in eClinicalMedicine, found that omega-3 fatty acids were associated with a statistically significant reduction in cardiovascular mortality (RR 0.93, 95% CI 0.88 to 0.98). EPA monotherapy showed larger relative risk reductions than EPA+DHA combined. The Harvard Gazette summarized the findings: omega-3 fatty acids reduced cardiovascular mortality and improved cardiovascular outcomes in this comprehensive pooled analysis.

One caveat worth noting: omega-3s were also associated with a modestly increased risk of atrial fibrillation (RR 1.26), particularly at higher doses. This tradeoff warrants discussion with a physician for anyone with AFib risk factors.

Practical guidance: 1 to 2 g of combined EPA+DHA per day from fish oil or algae-based sources, with meals containing fat to improve absorption.

Vitamin D (If Deficient)

The VITAL trial, a nationwide US RCT of 25,871 adults randomized to vitamin D3 at 2,000 IU per day or placebo, led by JoAnn Manson at Brigham and Women's Hospital, found no significant reduction in the primary endpoints of cancer incidence or major cardiovascular events. However, secondary analyses showed a significant reduction in cancer mortality when the first 1 to 2 years of follow-up were excluded (HR 0.75 after excluding the first 2 years).

The key modifier is baseline status. People with genuine vitamin D deficiency (serum 25-OH vitamin D below 20 ng/mL) gain measurable immune, bone, and possibly cardiometabolic benefits from correction. Supplementing someone with already-adequate levels produces smaller or negligible benefits. Checking your level before supplementing is more informative than taking 5,000 IU preventively and hoping.

Magnesium Glycinate

Magnesium is a cofactor in over 300 enzymatic reactions, including ATP production, DNA repair, and neuromuscular signaling. Deficiency is common in Western populations: estimates suggest 45 to 75 percent of adults in the US fall below recommended intakes based on dietary surveys. The glycinate chelate form has higher bioavailability than oxide and is better tolerated gastrointestinally.

Evidence for sleep improvement is covered in the longevity sleep protocol. For general metabolic and cardiovascular health, magnesium sufficiency is associated with lower all-cause mortality in observational data, though RCTs specifically targeting mortality are sparse.

Protein Adequacy (Not a Supplement Effect)

This category is often framed as a "whey supplement" recommendation, but the mechanism is nutritional adequacy rather than pharmacology. Most adults over 60 consume insufficient protein relative to their lean mass needs. The anabolic sensitivity of aging muscle to protein is reduced, requiring higher per-meal doses (30+ g) to maximally stimulate muscle protein synthesis compared to younger adults.

Whey protein, due to its high leucine content and rapid digestibility, is an efficient way to meet targets. Any complete protein source achieves the same biology. The longevity angle is again via sarcopenia prevention.

---

The Medium Evidence Tier: Promising but Incomplete

Curcumin (Bioavailable Formulations)

Curcumin has demonstrated anti-inflammatory and antioxidant effects in cell and animal models, and some human RCTs show reductions in inflammatory biomarkers (CRP, IL-6) in at-risk populations. The challenge is poor oral bioavailability of standard curcumin formulations: most is metabolized before systemic absorption. Phytosome or nanoparticle formulations improve this. Clinical evidence for hard longevity endpoints in humans is absent.

Glycine

Glycine at 3 g before sleep has been studied in small RCTs showing improvements in self-reported sleep quality and reduction in daytime fatigue. The 2025 magnesium bisglycinate trial noted glycine's sleep-supporting mechanisms as a contributing factor. As a conditionally essential amino acid involved in collagen synthesis and glutathione production, it is low-risk and inexpensive. Clinical evidence for longevity outcomes is limited.

Taurine

The most-cited paper on taurine and longevity is a 2023 study published in Science by Singh and colleagues, which found that taurine supplementation extended median lifespan in mice by 10 to 12 percent and improved multiple healthspan markers in mice and non-human primates. The authors explicitly called for long-term, well-controlled human clinical trials as a necessary next step.

A key complication emerged in 2025: a follow-up analysis in Science found that in healthy humans studied longitudinally, circulating taurine does not consistently decline with age in the way observed in mice, and inter-individual variability in taurine levels exceeds longitudinal change in most cohorts. This substantially weakens the rationale for universal supplementation in the absence of documented deficiency. Taurine is conditionally essential, broadly safe at typical doses (1 to 3 g/day), and mechanistically interesting. The human translation of the mouse lifespan data is not established.

---

The Popular but Weak Evidence Tier

NMN and NR (NAD+ Precursors)

NMN and NR reliably raise blood NAD+ levels in humans. This is well-established across multiple short-term RCTs, including a study showing that both compounds roughly double circulating NAD+ after 14 days compared to placebo. What has not been established is whether raising NAD+ through these precursors translates into meaningful longevity or healthspan outcomes in humans.

The NIA Interventions Testing Program tested nicotinamide riboside (NR) in genetically heterogeneous mice and found no significant extension of lifespan despite promising cellular data. Human trials to date have been short, small, and powered for biomarker outcomes rather than hard clinical endpoints. The evidence for spending significant money on NMN or NR for longevity is, at this time, weak.

Resveratrol

Resveratrol became famous following David Sinclair's sirtuin research in the early 2000s, with headlines connecting it to wine and longevity. GSK acquired the resveratrol company Sirtris for $720 million in 2008. After a series of failed phase II clinical trials across multiple conditions, GlaxoSmithKline discontinued the program in 2013. The compound has poor bioavailability, rapid hepatic metabolism, and has not demonstrated meaningful clinical benefit in any adequately powered human RCT.

NAD+ IV Infusion

No published evidence supports IV NAD+ infusions as a longevity intervention. Oral and IV routes raise blood NAD+ comparably at similar total doses. IV administration carries additional procedural risk for no established benefit over oral supplementation. Clinics offering "NAD+ drips" are marketing well ahead of the science.

---

The Prescription-Only Tier: Significant Promise, Significant Caveats

Rapamycin

Rapamycin (sirolimus) is an FDA-approved mTOR inhibitor used in organ transplantation that has produced the most robust lifespan extension data of any compound tested by the NIA's Interventions Testing Program. Across multiple independent ITP studies, rapamycin extended median lifespan in mice by 9 to 26 percent in females and 9 to 23 percent in males, even when treatment started late in the animals' lives.

Human longevity trials do not yet exist. Off-label low-dose rapamycin use is growing in longevity medicine circles based on the animal data and a favorable safety profile at weekly or intermittent dosing. The immunosuppressive effects, potential for impaired wound healing, and metabolic side effects at immunosuppressive doses are real clinical concerns. This is a prescription medication that requires physician supervision, full disclosure of known risks, and monitoring.

Metformin

Metformin is an off-patent biguanide used for type 2 diabetes management for over 60 years, with a well-characterized safety profile. Observational data consistently show that diabetic patients on metformin live longer than diabetic patients on other medications, and in some analyses, longer than age-matched non-diabetic populations not on the drug. The mechanism likely involves AMPK activation and mTOR inhibition.

The TAME (Targeting Aging with Metformin) trial, led by Nir Barzilai at the American Federation for Aging Research, is a nationwide six-year clinical trial at 14 institutions recruiting 3,000+ adults aged 65 to 79. It will test whether metformin delays the onset of age-related chronic diseases: cancer, cardiovascular disease, cognitive decline. Results are expected in the late 2020s. Until TAME reports, metformin's longevity evidence in non-diabetic humans rests on observational data, not RCT outcomes.

Metformin is not appropriate for everyone: it is contraindicated in significant renal impairment and can cause B12 deficiency with long-term use. It is a prescription medication.

---

How to Test Whether a Supplement Is Working for You

Without objective tracking, subjective experience of supplements is highly susceptible to placebo effects and regression to the mean. A basic protocol: establish a 4-week baseline of whatever metric you are targeting (sleep quality, HRV trend, workout performance, inflammatory marker if you have lab access), introduce the supplement in a single-variable change, track the same metric for 8 weeks, and compare. For anything affecting sleep or recovery, a wearable that tracks HRV and sleep consistency provides the most actionable signal.

---

Frequently Asked Questions

What supplement has the strongest evidence for healthy aging? Creatine monohydrate, for its well-documented effects on preserving muscle mass and strength during aging, supported by multiple RCTs and meta-analyses in older adults. For cardiovascular outcomes, omega-3 EPA and DHA have a robust 38-RCT meta-analytic evidence base.

Should I take NMN for longevity? NMN raises NAD+ levels in humans, but there is no RCT evidence that this translates into longevity or healthspan outcomes in people. The NIA's ITP found no lifespan benefit from NR in mice. NMN is not harmful at typical doses, but spending significant money on it for longevity is not currently evidence-supported.

Is rapamycin safe to take without a doctor? No. Rapamycin is an immunosuppressant with real side effects including impaired wound healing, metabolic effects, and infection risk. It requires physician oversight, monitoring, and informed consent about known risks and absent long-term human safety data for off-label longevity use.

How do I know if I am vitamin D deficient? A 25-OH vitamin D blood test, available through your primary care physician or direct-to-consumer lab services. Levels below 20 ng/mL are generally considered deficient; levels below 30 ng/mL are often considered insufficient.

Is the TAME trial finished? No. As of 2025, the TAME trial is ongoing. It is a six-year study and results are expected in the late 2020s. Until then, metformin's longevity effects in non-diabetic humans are not established by controlled trial data.

---

Vaya Chat can help you evaluate your current supplement protocol against the evidence, flag potential interactions, and identify which biomarkers to track to assess whether what you are taking is doing anything measurable. Plans start at $10 per month or $89 per year at vidaya.ai.

---

Related reading:

• The Longevity Sleep Protocol
• Longevity Protocols Overview
• Wearable Insights: Tracking Your Health Data
• Sharing Medical Records with AI

---